Login / Signup
Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).
Sepideh Attal
Jason Kemner
Jose Alvir
Sebastian Barth
Sofia Schuessler
Published in:
Cardiology and therapy (2024)
In the IQVIA™ LRx database, patients prescribed tafamidis 61 mg in Germany displayed high adherence and persistency rates, which suggest good drug tolerability and ease of use.
Keyphrases
</>
health insurance
end stage renal disease
affordable care act
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
case report
clinical trial
adverse drug
electronic health record
randomized controlled trial
healthcare
big data
metabolic syndrome
type diabetes
machine learning
data analysis
patient reported